Mode of action

The IL-17 pathway

Skin keratinocytes produce IL-17C which stimulates Th17 cells to produce IL-17A and IL-17F, which further stimulate keratinocytes to produce more IL-17C – creating a positive feedback loop.3

Kyntheum® is the first therapy for moderate to severe plaque psoriasis that selectively targets the IL-17RA subunit, thereby blocking the inflammatory signalling of IL-17A, IL-17F, IL-17A/F,
IL-17E and IL-17C.1,2

By blocking multiple IL-17 ligands, Kyntheum® achieves rapid normalisation of inflammatory markers in keratinocytes, which in turn slows down hyperproliferation of the skin and helps restore normal skin function.1-10

How Kyntheum® Works

Whats unique about Kyntheum®?

What makes the mode of action of Kyntheum® different?

Mode of action of Kyntheum®

Return to the product page

IL=Interleukin; Th=helper cell

1. Kyntheum® SmPC.
2. Baker KF and Isaacs JD. Ann Rheum Dis 2018;77:175–87.
3. Guttman-Yassky E. and Krueger JG. J Invest Dermatol 2018;138(7):1467–1469.
4. Nestle FO, et al. N Engl J Med 2009;361:496–509.
5. Brembilla NC, et al. Front Immunol 2018;9:1682.
6. Pappu R, et al. Immunology 2011;134:8–16.
7. Senra L, et al. J Invest Dermatol 2016;136(10):1970–80.
8. Johnston A, et al. J Immunol 2013;190:2252–62.
9. Wilke CM, et al. Trends Immunol 2011;32:12.
10. Russel et al. J Immunol 2014; 192:3828-3836.

MAT-42310 Jan 2021